Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.

BACKGROUND Vulvar intraepithelial neoplasia is a chronic disorder caused by high-risk types of human papillomavirus (HPV), most commonly HPV type 16 (HPV-16). Spontaneous regression occurs in less than 1.5% of patients, and the rate of recurrence after treatment is high. METHODS We investigated the immunogenicity and efficacy of a synthetic long-peptide vaccine in women with HPV-16-positive, high-grade vulvar intraepithelial neoplasia. Twenty women with HPV-16-positive, grade 3 vulvar intraepithelial neoplasia were vaccinated three or four times with a mix of long peptides from the HPV-16 viral oncoproteins E6 and E7 in incomplete Freund's adjuvant. The end points were clinical and HPV-16-specific T-cell responses. RESULTS The most common adverse events were local swelling in 100% of the patients and fever in 64% of the patients; none of these events exceeded grade 2 of the Common Terminology Criteria for Adverse Events of the National Cancer Institute. At 3 months after the last vaccination, 12 of 20 patients (60%; 95% confidence interval [CI], 36 to 81) had clinical responses and reported relief of symptoms. Five women had complete regression of the lesions, and HPV-16 was no longer detectable in four of them. At 12 months of follow-up, 15 of 19 patients had clinical responses (79%; 95% CI, 54 to 94), with a complete response in 9 of 19 patients (47%; 95% CI, 24 to 71). The complete-response rate was maintained at 24 months of follow-up. All patients had vaccine-induced T-cell responses, and post hoc analyses suggested that patients with a complete response at 3 months had a significantly stronger interferon-gamma-associated proliferative CD4+ T-cell response and a broad response of CD8+ interferon-gamma T cells than did patients without a complete response. CONCLUSIONS Clinical responses in women with HPV-16-positive, grade 3 vulvar intraepithelial neoplasia can be achieved by vaccination with a synthetic long-peptide vaccine against the HPV-16 oncoproteins E6 and E7. Complete responses appear to be correlated with induction of HPV-16-specific immunity.

[1]  J. Woodruff,et al.  The Predominance of Human Papillomavirus Type 16 in Vulvar Neoplasia , 1988, Obstetrics and gynecology.

[2]  A. Östör,et al.  Natural history of cervical intraepithelial neoplasia: a critical review. , 1993, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[3]  A. Ostör.  Natural history of cervical intraepithelial neoplasia: a critical review. , 1993, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[4]  J. Bouwes Bavinck,et al.  Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. , 1993, Journal of virological methods.

[5]  R. Ahmed,et al.  CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection , 1994, Journal of virology.

[6]  C. Meijer,et al.  The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. , 1995, The Journal of general virology.

[7]  Multifocal vulvar intraepithelial neoplasia grade III and multicentric lower genital tract neoplasia is associated with transcriptionally active human papillomavirus , 1995, Cancer.

[8]  J. Junge,et al.  Vulvar intraepithelial neoplasia III: a viral disease of undetermined progressive potential. , 1995, Gynecologic oncology.

[9]  M I Shafi,et al.  Vulvar intraepithelial neoplasia: long term follow up of treated and untreated women , 1996, British journal of obstetrics and gynaecology.

[10]  B. Moss,et al.  Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. , 1997, The Journal of infectious diseases.

[11]  A. Fiander,et al.  Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. , 1997, Cancer research.

[12]  R. Ahmed,et al.  Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. , 1998, Current opinion in immunology.

[13]  A. Moscicki,et al.  Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. , 2000, The Journal of infectious diseases.

[14]  Harald zur Hausen,et al.  Papillomaviruses Causing Cancer: Evasion From Host-Cell Control in Early Events in Carcinogenesis , 2000 .

[15]  S. H. van der Burg,et al.  Natural T‐helper immunity against human papillomavirus type 16 (hpv16) e7–derived peptide epitopes in patients with hpv16‐positive cervical lesions: Identification of 3 human leukocyte antigen class ii–restricted epitopes , 2001, International journal of cancer.

[16]  C J L M Meijer,et al.  The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.

[17]  P. Porter,et al.  A population-based study of squamous cell vaginal cancer: HPV and cofactors. , 2002, Gynecologic oncology.

[18]  P. Snijders,et al.  GP5+/6+ PCR followed by Reverse Line Blot Analysis Enables Rapid and High-Throughput Identification of Human Papillomavirus Genotypes , 2002, Journal of Clinical Microbiology.

[19]  S. H. van der Burg,et al.  Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides1 , 2002, The Journal of Immunology.

[20]  J. M. van der Hulst,et al.  Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. , 2002, Cancer research.

[21]  S. H. van der Burg,et al.  Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  H. Kitchener,et al.  Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. , 2003, Cancer research.

[23]  J. M. van der Hulst,et al.  Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. , 2003, Cancer research.

[24]  S. H. van der Burg,et al.  Immunological Responses in Women with Human Papillomavirus Type 16 (HPV-16)-Associated Anogenital Intraepithelial Neoplasia Induced by Heterologous Prime-Boost HPV-16 Oncogene Vaccination , 2004, Clinical Cancer Research.

[25]  I. Frazer,et al.  Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. , 2004, Vaccine.

[26]  J. M. van der Hulst,et al.  Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 , 2004, Cancer Research.

[27]  S. H. van der Burg,et al.  Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. , 2005, Vaccine.

[28]  A. Craen,et al.  Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. , 2005, Gynecologic oncology.

[29]  Vulvar Intraepithelial Neoplasia: Aspects of the Natural History and Outcome in 405 Women , 2005, Obstetrics and gynecology.

[30]  A. D. de Craen,et al.  Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. , 2005, Gynecologic oncology.

[31]  S. H. van der Burg,et al.  Detection of Human Papillomavirus (HPV) 16-Specific CD4+ T-cell Immunity in Patients with Persistent HPV16-Induced Vulvar Intraepithelial Neoplasia in Relation to Clinical Impact of Imiquimod Treatment , 2005, Clinical Cancer Research.

[32]  M. Stoler,et al.  The Distribution of Low and High-risk HPV Types in Vulvar and Vaginal Intraepithelial Neoplasia (VIN and VaIN) , 2006, The American journal of surgical pathology.

[33]  C. Melief,et al.  Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines , 2008, Nature Reviews Cancer.

[34]  S. H. van der Burg,et al.  Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine , 2008, Clinical Cancer Research.

[35]  J. M. van der Hulst,et al.  Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell Response , 2008, Clinical Cancer Research.

[36]  N. Aaronson,et al.  Treatment of vulvar intraepithelial neoplasia with topical imiquimod. , 2008, The New England journal of medicine.

[37]  S. H. van der Burg,et al.  Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity , 2008, Clinical Cancer Research.

[38]  M. Madeleine,et al.  A Systematic Review of the Prevalence and Attribution of Human Papillomavirus Types among Cervical, Vaginal, and Vulvar Precancers and Cancers in the United States , 2008, Cancer Epidemiology Biomarkers & Prevention.